The proteome signature of the inflammatory breast cancer plasma membrane identifies novel molecular markers of disease
- 1 January 2016
- journal article
- research article
- Vol. 6 (8) , 1720-1740
Abstract
Inflammatory Breast Cancer (IBC) is the most lethal form of breast cancer with a 35% 5-year survival rate. The accurate and early diagnosis of IBC and the development of targeted therapy against this deadly disease remain a great medical challenge. Plasma membrane proteins (PMPs) such as E-cadherin and EGFR, play an important role in the progression of IBC. Because the critical role of PMPs in the oncogenic processes they are the perfect candidates as molecular markers and targets for cancer therapies. In the present study, Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) followed by mass spectrometry analysis was used to compare the relative expression levels of membrane proteins (MP) between non-cancerous mammary epithelial and IBC cells, MCF-10A and SUM-149, respectively. Six of the identified PMPs were validated by immunoblotting using the membrane fractions of non-IBC and IBC cell lines, compared with MCF-10A cells. Immunohistochemical analysis using IBC, invasive ductal carcinoma or normal mammary tissue samples was carried out to complete the validation method in nine of the PMPs. We identified and quantified 278 MPs, 76% of which classified as PMPs with 1.3-fold or higher change. We identified for the first time the overexpression of the novel plasminogen receptor, PLGRKT in IBC and of the carrier protein, SCAMP3. Furthermore, we describe the positive relationship between L1CAM expression and metastasis in IBC patients and the role of SCAMP3 as a tumor-related protein. Overall, the membrane proteomic signature of IBC reflects a global change in cellular organization and suggests additional strategies for cancer progression. Together, this study provides insight into the specialized IBC plasma membrane proteome with the potential to identify a number of novel therapeutic targets for IBC.Keywords
This publication has 49 references indexed in Scilit:
- Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer ProgressionJournal of Cancer, 2016
- The multifaceted role of CD146/MCAM in the promotion of melanoma progressionCancer Cell International, 2015
- Plasma Membrane Proteomics of Human Breast Cancer Cell Lines Identifies Potential Targets for Breast Cancer Diagnosis and TreatmentPLOS ONE, 2014
- Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addictionJournal of Biomedical Research, 2013
- L1CAMCell Adhesion & Migration, 2012
- Regulation of macrophage migration by a novel plasminogen receptor Plg-RKTBlood, 2011
- SCAMP3 Negatively Regulates Epidermal Growth Factor Receptor Degradation and Promotes Receptor RecyclingMolecular Biology of the Cell, 2009
- CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell linesBreast Cancer Research, 2009
- Prognostic significance of HER‐2 status in women with inflammatory breast cancerCancer, 2008
- Prognostic Significance of Co-expression of RON and MET Receptors in Node-Negative Breast Cancer PatientsClinical Cancer Research, 2005